ストックスクリーナーアプリを入手
4.24
3.98%
-0.16
前日終値:
$4.40
開ける：
$4.43
24時間の取引高:
106.00K
Relative Volume:
0.31
時価総額：
$267.13M
収益：
$12.14M
当期純損益:
$-99.50M
株価収益率:
-3.1322
EPS:
-1.3537
ネットキャッシュフロー:
$-56.37M
1週間 パフォーマンス:
+22.11%
1か月 パフォーマンス:
+17.36%
6か月 パフォーマンス:
+235.32%
1年 パフォーマンス:
+558.30%
1日の値動き範囲:
$4.20
$4.62
1週間の範囲:
$3.48
$4.815
52週間の値動き範囲:
$0.6445
$4.815
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.24 | 277.21M | 12.14M | -99.50M | -56.37M | -1.3537 |
VRTX
Vertex Pharmaceuticals Inc
|
436.81 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.43 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.62 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
324.99 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.38 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 開始されました | Jefferies | Buy |
| 2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-26 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Goldman | Neutral |
| 2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
Retail Surge: Is Prelude Therapeutics Incorporated a turnaround story2026 Drop Watch & Consistent Income Trade Recommendations - baoquankhu1.vn
Loss Report: How do insiders feel about Prelude Therapeutics IncorporatedExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
IPO Launch: Will Prelude Therapeutics Incorporated stock go up in YEARMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN
PRLD Technical Analysis & Stock Price Forecast - Intellectia AI
Rate Hike: Is Prelude Therapeutics Incorporated backed by strong institutional buying2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World
If You Invested $1,000 in Prelude Therapeutics Inc (PRLD) - Stock Titan
PRLD PE Ratio & Valuation, Is PRLD Overvalued - Intellectia AI
Value Recap: How do insiders feel about Prelude Therapeutics IncorporatedChart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - Yahoo Finance
Prelude Therapeutics Reports 2025 Results and Advances Oncology Pipeline - MyChesCo
Prelude Therapeutics Inc. Files Form 8-K with SEC – Company Information and Legal Exhibit Details (March 12, 2026) - Minichart
Prelude Therapeutics Establishes New ATM Equity Offering Facility - The Globe and Mail
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies By Investing.com - Investing.com South Africa
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com
Prelude Therapeutics 2025 Annual Report: Precision Oncology Pipeline, Business Strategy, and Regulatory Overview - Minichart
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet
Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat
Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus
Citizens raises Prelude Therapeutics price target on JAK2 potential By Investing.com - Investing.com Canada
Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - simplywall.st
PRLD: Pipeline refocused on JAK2 V617F and KAT6A, with strong funding and key Incyte partnership - TradingView
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M - AlphaStreet
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates - AlphaStreet
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics 2025 10-K: Revenue $12.14M, EPS (1.29) - TradingView
Prelude Therapeutics (NASDAQ:PRLD) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
PRLD: Secured $60M upfront from Incyte, boosting cash and extending runway into Q2 2027 - TradingView
Prelude Therapeutics (PRLD) Advances Key Drug Programs with IND Clearance - GuruFocus
Prelude Therapeutics Earnings Report: Q4 Overview - Benzinga
Prelude Therapeutics reports $99.5 mln net loss for 2025 - TradingView
BRIEF-Prelude Therapeutics FY EPS USD -1.29 - TradingView
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - ChartMill
Aug Analyst Calls: Can Prelude Therapeutics Incorporated outperform under higher oil prices2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Prelude Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Volume Report: Is Prelude Therapeutics Incorporated a cyclical or defensive stockQuarterly Earnings Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday - MarketBeat
PRLD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Wrap: Is Prelude Therapeutics Incorporated backed by strong institutional buyingMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Quarterly Risk: Does Prelude Therapeutics Incorporated have consistent dividend growthJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Guidance Update: Is Prelude Therapeutics Incorporated stock trending bullishTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times
What’s the beta of Prelude Therapeutics Incorporated stock2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
0.41%
大文字化:
|
ボリューム (24 時間):